Director at Theravance Biopharma (TBPH) receives new share and option awards

Q: What insider transaction did Theravance Biopharma (TBPH) report for Donal O'Connor?

Theravance Biopharma reported that director Donal O'Connor received new equity awards. He was granted 6,009 Ordinary Shares at no cost and a share option covering 13,398 Ordinary Shares as part of his compensation on June 12, 2026 .

Q: How many Theravance Biopharma (TBPH) shares does Donal O'Connor hold after the Form 4 transaction?

After the reported awards, Donal O'Connor directly holds 80,213 Ordinary Shares of Theravance Biopharma. This figure reflects his position following the 6,009-share grant disclosed, and is separate from the 13,398 shares underlying his new stock option.

Q: What are the key terms of Donal O'Connor's new stock option at Theravance Biopharma (TBPH)?

The new stock option covers 13,398 Ordinary Shares with an exercise price of $16.64 per share . It expires on June 11, 2036 and, if vested and exercised, would allow him to buy Theravance Biopharma shares at that fixed price.

Q: How does the stock option granted to Donal O'Connor at Theravance Biopharma (TBPH) vest?

The option vests over time based on continued service. 1/12 of the shares subject to the option vest after each continuous month of service, and any remaining unvested shares vest on the date of the next annual shareholders’ meeting if he remains in continuous service.

Q: Is Donal O'Connor’s Form 4 for Theravance Biopharma (TBPH) a market purchase or sale?

The Form 4 reflects grants/awards , not open-market trades. The code “A” indicates a grant, award, or other acquisition, so the 6,009-share award and 13,398-share option were received as compensation rather than bought or sold in the market.

Q: What type of security is underlying Donal O'Connor’s new option in Theravance Biopharma (TBPH)?

The option is a Share Option (Right to Buy) that can convert into Ordinary Shares . It covers 13,398 underlying Ordinary Shares , which O'Connor may purchase at $16.64 per share if the option is vested and he chooses to exercise it.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Theravance Biopharma director Donal O'Connor received new equity awards. On June 12, 2026, he was granted 6,009 Ordinary Shares at no cost, increasing his direct holdings to 80,213 Ordinary Shares.

He was also granted a share option for 13,398 Ordinary Shares at an exercise price of $16.64 per share, expiring on June 11, 2036. According to the vesting terms, 1/12 of the option shares vest after each continuous month of service following the grant date, with any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders, provided he remains in continuous service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider O'Connor Donal

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	13,398	$0.00	--
Grant/Award	Ordinary Shares	6,009	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 13,398 shares (Direct, null); Ordinary Shares — 80,213 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Share grant: 6,009 Ordinary Shares Total shares after grant: 80,213 Ordinary Shares Option size: 13,398 shares +3 more

6 metrics

Share grant 6,009 Ordinary Shares Award to director Donal O'Connor on June 12, 2026

Total shares after grant 80,213 Ordinary Shares Direct holdings following share award

Option size 13,398 shares Share Option (Right to Buy) granted June 12, 2026

Option exercise price $16.64 per share Conversion or exercise price for new option

Option expiration June 11, 2036 Expiration date of Share Option (Right to Buy)

Option vesting rate 1/12 per month Portion of option shares vesting after each month of continuous service

Key Terms

Share Option (Right to Buy), Ordinary Shares, grant/award acquisition, continuous month of service, +1 more

5 terms

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

continuous month of service financial

"when optionee completes each continuous month of service following the grant date"

annual meeting of the company's shareholders financial

"vest on the date of the next annual meeting of the company's shareholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/16/2026 - 09:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor Donal

(Last)

(First)

(Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/12/2026		A		6,009	A	$0	80,213	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (Right to Buy)	$16.64	06/12/2026		A		13,398		⁽¹⁾	06/11/2036	Ordinary Shares	13,398	$0	13,398	D

Explanation of Responses:

1. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

	/s/ Brett A. Grimaud, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Theravance Biopharma (TBPH) report for Donal O'Connor?

Theravance Biopharma reported that director Donal O'Connor received new equity awards. He was granted 6,009 Ordinary Shares at no cost and a share option covering 13,398 Ordinary Shares as part of his compensation on June 12, 2026.

How many Theravance Biopharma (TBPH) shares does Donal O'Connor hold after the Form 4 transaction?

After the reported awards, Donal O'Connor directly holds 80,213 Ordinary Shares of Theravance Biopharma. This figure reflects his position following the 6,009-share grant disclosed, and is separate from the 13,398 shares underlying his new stock option.

What are the key terms of Donal O'Connor's new stock option at Theravance Biopharma (TBPH)?

The new stock option covers 13,398 Ordinary Shares with an exercise price of $16.64 per share. It expires on June 11, 2036 and, if vested and exercised, would allow him to buy Theravance Biopharma shares at that fixed price.

How does the stock option granted to Donal O'Connor at Theravance Biopharma (TBPH) vest?

The option vests over time based on continued service. 1/12 of the shares subject to the option vest after each continuous month of service, and any remaining unvested shares vest on the date of the next annual shareholders’ meeting if he remains in continuous service.

Is Donal O'Connor’s Form 4 for Theravance Biopharma (TBPH) a market purchase or sale?

The Form 4 reflects grants/awards, not open-market trades. The code “A” indicates a grant, award, or other acquisition, so the 6,009-share award and 13,398-share option were received as compensation rather than bought or sold in the market.

What type of security is underlying Donal O'Connor’s new option in Theravance Biopharma (TBPH)?

The option is a Share Option (Right to Buy) that can convert into Ordinary Shares. It covers 13,398 underlying Ordinary Shares, which O'Connor may purchase at $16.64 per share if the option is vested and he chooses to exercise it.